To study the impact of T-cells and B-cells on the synergy and radiosensitization of dual trastuzumab and cetuximab combination therapy, experiments conducted in a humanized model of HER2+/EGFR+ HNSCC could be pursued. Here, ERBB2 is linked to head and neck squamous cell carcinoma.